Healthcare
Moderna says FDA to review its flu vaccine after reversing course
With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.


Glideslope AI-powered market news
No market stories in the last 7 days. The latest coverage is below.

No scored stories in the last 7 days.
| Day | Mood | Stories |
|---|---|---|
| Sat, Oct 10 | — | 0 |
| Fri, Oct 9 | — | 0 |
| Thu, Oct 8 | — | 0 |
| Wed, Oct 7 | — | 0 |
| Tue, Oct 6 | — | 0 |
| Mon, Oct 5 | — | 0 |
| Sun, Oct 4 | — | 0 |
| Sat, Oct 3 | — | 0 |
With the reversal from the FDA, Moderna said it is aiming to make the vaccine available for the 2026-27 flu season.

A notable event occurred between early Sunday and early Monday, when at least six vessels diverted their courses.

Unlock the AI Macro Analyst to drill down into the data, explore hidden risks, and query the entire market briefing in real-time.
LOG IN / SUBSCRIBE